Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane

Circulation Research

Volumn 84, Issue 3, 1999, Pages 257-265

  Sawyer, Douglas B ^a,b   Fukazawa, Ryuji ^a   Arstall, Margaret A ^a,c   Kelly, Ralph A ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antioxidant; Cardiotoxicity; Dexrazoxane; Superoxide anion

Indexed keywords

DAUNORUBICIN; RAZOXANE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL PROTECTION; CONCENTRATION RESPONSE; CYTOPATHOGENIC EFFECT; DRUG EFFECT; HEART MUSCLE CELL; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TOXICITY TESTING;

EID: 0033014821     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.3.257     Document Type: Article

References (52)

1. Praga C, Beretta G, Vigo PL. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979;63:827-834.
2. Von Hoff DD, Layard MW, Basa P, Davis H, Van Hoff AL, Rozensweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
3. Buzdar AU, Marcus C, Smith TL, Blumenshein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer Res. 1985;55:2761-2765.
4. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Nyers CE, Barr LH, Schwartz DE, Bacharach SL, Green MV, Rosenberg SA. Doxorubicin cardiotoxicity: assessment of the left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med. 1981;94:430-435.
5. Julicher RHM, van der Laarse A, Sterrenberg L, Bloys van Treslong CHF, Bast A, Noordhoek J. The involvement of an oxidative mechanism in the Adriamycin induced toxicity in neonatal rat heart cell cultures. Res Commun Chem Pathol Pharmacol. 1985;47:35-47.
6. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990;4:3076-3086.
7. Abdel-aleem S, El-Merzabani MM, Sayed-Ahmed M, Taylor DA, Lowe JE. Acute and chronic effects of Adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol. 1997;29:789-797.
8. Doroshow JH, Davies KJA. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem. 1986;261:3068-3074.
9. Dolem LE, Heller LJ, Wallace KB. Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. J Mol Cell Cardiol. 1996;28:1023-1032.
10. Singal PK, Panagia V. Direct effects of Adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol. 1984;43:67-77.
11. Kurabayashi M, Jeyaseelan R, Kedes L. Antineoplastic agent doxorubicin inhibits myogenic differentiation of C2 myoblasts. J Biol. 1993;268: 5524-5529.
12. Kurabayashi M, Jeyaseelan R, Kedes L. Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor MyoD. J Biol Chem. 1994;269:6031-6039.
13. Kurabayashi M, Dutta S, Jeyaseelan R, Kedes L. Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/ cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Mol Cell Biol. 1995;15:6386-6397.
14. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980;65:128-135.
15. Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest. 1981; 68:1053-1064.
16. Breed JG, Zimmerman AN, Dormans JA, Pinedo HM. Failure of the antioxidant vitamin E to protect against Adriamycin-induced cardiotoxicity in the rabbit. Cancer Res. 1980;40:2033-2038.
17. Fujita K, Shinpo K, Yamada K, Sato T, Niimi H, Shamoto M, Nagatsu T, Takeuchi T, Umezawa H. Reduction of Adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res. 1982;42:309-316.
18. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, Wernz J, Feit F, Slater W, Blum R, Muggia F. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988;319:745-752.
19. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 1995;82:405-414.
20. Skladanowski A, Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells. Biochem Pharmacol. 1993;46:375-382.
21. Simmons WW, Cross EI, Cunningham JM, Smith TW, Kelly RA. Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes. J Biol Chem. 1996;271:11694-11702.
22. Springhorn JP, Claycomb WC. Preproenkephalin mRNA expression in developing rat heart and in cultured ventricular cardiac muscle cells. Biochem J. 1989;258:73-78.
23. Olive PL, Wlodek D, Banath JP. DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. Cancer Res. 1991;51: 4671-4676.
24. Telford WG, King LE, Fraher P. Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. J Cell Prolif. 1991;24:447-459.
25. Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am J Physiol. 1996;271:H2079-H2085.
26. Burow S, Valet G. Flow-cytometric characterization of stimulation, free radical formation, peroxidase activity and phagocytosis of human granulocytes with 2,7,-dichlorofluorescein (DCF). Eur J Cell Biol. 1987;43: 128-133.
27. Zhu H, Bannerberg G, Modeus P, Shertzer H. Oxidation pathways for the intracellular probe 2′,7′-dichlorofluorescein. Arch Toxicol. 1994;68: 582-587.
28. Benov L, Fridovich I. Functional significance of the Cu,ZnSOD in Escherichia coli. Arch Biochem Biophys. 1996;327:249-253.
29. Faulkner KM, Kiochev SI, Fridovich I. Stable Mn(III) porphyrins mimic superoxide dismutase in vitro and substitute for it in vivo. J Biol Chem. 1994;269:23471-23476.
30. Imondi AR, Della Rorre P, Mazue B, Sullivan TM, Robbins RL, Hagerman LM, Podesta A, Pinciroli G. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res. 1996;56:4200-4204.
31. Tobin TP, Abbott BC. A stereological analysis of the effect of Adriamycin on the ultrastructure of rat myocardial cells in culture. J Mol Cell Cardiol. 1980;12:1207-1225.
32. Lampidis TJ, Henderson IC, Israel M, Canellos GP. Structural and functional effects of Adriamycin on cardiac cells in vitro. Cancer Res. 1980; 40:3901-3909.
33. Newman RA, Hacker MP, Krakoff IH. Amelioration of Adriamycin and daunorubicin myocardial toxicity by adenosine. Cancer Res. 1981;41: 3483-3488.
34. Keung EC, Toll L, Ellis M, Jensen RA. L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats: morphological, biochemical, and functional correlations. J Clin Invest. 1991;87:2108-2113.
35. Kurabayashi M, Dutta S, Jeyaseelan R, Kedes L. Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/ cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Mol Cell Biol. 1995;15:6386-6397.
36. Jeyaseelan R, Poizat C, Baker RK, Abdishoo S, Isterabad LB, Lyons GF, Kedes L. A novel cardiac-restricted target for doxorubicin. J Biol Chem. 1997;272:22800-22808.
37. Jeyaseelan R, Poizat C, Wu H-Y, Kedes L. Molecular mechanisms of doxorubicin-induced cardiomyopathy: selective suppression of Reishe iron-sulfur protein, ADT/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem. 1997;272:5828-5832.
38. Zhang J, Clark JR Jr, Herman EH, Ferrans VJ. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol. 1996;28:1931-1943.
39. Unverferth DV, Magorien RD, Unverferth BP, Talley RL, Balcerzad SP, Baba N. Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep. 1981; 65:1093-1097.
40. Fukazawa R, Ogawa S, Hirayama T. Early detection of anthracycline cardiotoxicity in children with acme leukemia using exercise-based echocardiography and Doppler echocardiography. Jpn Circ J. 1994;58: 625-634.
41. Missor E, Pau B, Calzolari C. Increased circulating levels of cardiac troponin I in anthracycline-treated patients. Circulation. 1996;94(suppl I):I-732. Abstract.
42. Kalyanaraman B, Perez-Reyes E, Mason RP. Spin-trapping and direct electron spin resonance investigations of the redox metabolism of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta. 1988;630:119-130.
43. Davies KJA, Doroshow J. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem. 1986;261:3060-3067.
44. Thayer WS. Adriamycin stimulated superoxide formation in submitochondrial particles. Chem Biol Interact. 1977;19:265-278.
45. 2; an explanation for the cardiotoxicity of anthracycline antibiotics. Biochem Biophys Res Commun. 1983;114:197-205.
46. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988;48:4766-4769.
47. Buss JL, Hasinoff BB. The one-ring open hydrolysis product intermediates of the cardioprotective agent CRF-187 (dexrazoxane) displace iron from iron anthracycline complexes. Agents Actions. 1993;40:86-95.
48. 2, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6:593-597.
49. Jia L, Furchgott F. Inhibition by sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1993;267:371-378.
50. Tsai J-C, Jain M, Hsieh C-M, Lee W-S, Yoshizumi M, Patterson C, Perrella MA, Cooke C, Wang H, Haber E, Schlegel R, Lee M-E. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J Biol Chem. 1996; 271:3667-3670.
51. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med. 1992;175:1181-1194.
52. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against Adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest. 1996;98:1253-1260.